Navigation Links
Janssen Announces Collaboration with Vertex on Phase 2 Study to Investigate an All-Oral Regimen of Simeprevir (TMC435) and VX-135 for Treatment of Hepatitis C
Date:11/1/2012

TITUSVILLE, N.J., Nov. 1, 2012 /PRNewswire/ -- Janssen Pharmaceuticals, Inc. today announced that it has entered into a non-exclusive collaboration with Vertex Pharmaceuticals Incorporated to evaluate in a Phase 2 study the safety and efficacy of an all-oral regimen for the treatment of hepatitis C (HCV). The regimen will include Janssen's investigational protease inhibitor simeprevir (TMC435) and Vertex's investigational nucleotide analogue HCV polymerase inhibitor VX-135. As a first step, Janssen will conduct a drug-drug interaction (DDI) study with simeprevir and VX-135. The DDI study will support the initiation of the Phase 2 study in early 2013 pending discussions with regulatory authorities.

The goal of the Phase 2 study will be to evaluate the safety, tolerability and viral cure rates of a 12-week regimen of simeprevir and VX-135, administered with and without ribavirin, in treatment-naive patients who have chronic non-cirrhotic genotype 1 HCV. The companies will jointly fund development costs associated with the collaboration. There are no up-front or milestone payments associated with the agreement.

Simeprevir is an investigational NS3/4A protease inhibitor currently in Phase 3 trials, developed in collaboration with and licensed from Medivir AB. VX-135 is an investigational uridine nucleotide analogue pro-drug designed to inhibit the replication of HCV by acting on the NS5B polymerase. 

"There is a significant unmet need for all-oral treatment regimens for people living with hepatitis C," said Wim Parys, Global Head of Infectious Diseases at Janssen. "Janssen's collaboration with Vertex underscores our commitment to better understand the potential utility of simeprevir in a number of different interferon-free treatment combinations and HCV patient populations."

About Simeprevir
Simeprevir (TMC435) is an NS3/4A protease inhibitor jointly developed by Janssen and Medivir AB to treat chronic HCV infection. Simepr
'/>"/>

SOURCE Janssen Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. West Announces Agreement with Janssen Biotech to Develop and Commercialize a New Self-injection Technology
2. Janssen Biotech Announces Global License and Development Agreement for Investigational Anti-Cancer Agent Daratumumab
3. Janssen Announces Initiation Of Phase 3 Development Program For Sirukumab In Rheumatoid Arthritis
4. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin to Treat Patients with Type 2 Diabetes
5. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
6. Anthera Announces the Phase 2b PEARL-SC Data Has Been Accepted as a Late Breaking Poster Presentation at the ACR/ARHP 2012 Annual Scientific Meeting
7. Watson Announces Global Generics Management Team
8. Watson Announces New Name -- Actavis -- for Global Operations
9. BioMed Realty Announces 93,000 Square Foot Lease Expansion And Extension With Ironwood Pharmaceuticals At 301 Binney Street
10. Abaxis Announces Exclusive Distribution Agreement with Abbott
11. Thesan Pharmaceuticals Announces Series A Funding Co-Led By Novo Ventures And Novartis Venture Funds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... Oct. 20, 2014 CTI BioPharma Corp. (CTI) ... report its third quarter 2014 financial results on Wednesday, ... financial markets. Following the announcement, members of the management ... the results and provide a general corporate update at ... event can be obtained as follows: Wednesday, ...
(Date:10/17/2014)... N.C. , Oct. 17, 2014 ... the Medical Affairs function has come across several ... resources efficiently and managing globalization.  ... Practices, LLC is dedicated to providing benchmarking and ... Medical Affairs Consortium is a service composed of ...
(Date:10/17/2014)... UBM Medica US announces that Neurology Times ... for neurologists and other healthcare providers, features special coverage on ... discussions of the latest developments in approaches to diagnosis. ... , more than the total of those who have multiple ... can be difficult because there are no confirmatory medical tests. ...
Breaking Medicine Technology:CTI BioPharma to Report Third Quarter 2014 Financial Results on October 29, 2014 2Early Key Findings from the Medical Affairs Consortium Research 2Neurology Times Features Coverage of Parkinson and Alzheimer Disease 2Neurology Times Features Coverage of Parkinson and Alzheimer Disease 3
... N.J. , Jan. 25 PharmaNet Development Group, ... biotechnology, generic drug and medical device companies, announced today that ... Clinical Research Neuroscience. , "We are very pleased to ... , Chief Operating Officer, Late Stage Development. "Steve is a ...
... NEW YORK , Jan. 25 Stewart ... a substantial donation to charitable organizations helping the people of ... of pharmaceutical, generic, health & beauty and home health care ... according to 2009 Forbes Magazine. , Rahr was a primary ...
Cached Medicine Technology:Steven Leventer Joins PharmaNet Development Group as Vice President, Clinical Research Neuroscience 2Pharma Billionaire Stewart Rahr Provides Substantial Donation to Haiti Charities 2
(Date:10/20/2014)... National Teen Driver Safety Week is October 19-25, ... Pediatrics (Ohio AAP, http://www.ohioaap.org ) is joining the National ... drivers to talk to their teens and always set the ... are the leading cause of death for U.S. teens. In ... and 859 (42%) of those teen drivers were killed in ...
(Date:10/20/2014)... October 20, 2014 Punzoné , the ... the U.S., has a lot to celebrate this month. October ... recognizes the achievements and contributions of Americans of Italian heritage ... Punzoné, and today it shares its favorite Italian cocktails and ... to Italy - even if it is only in a ...
(Date:10/19/2014)... 20, 2014 The leading review ... http://www.top10bestseohosting.com/go/iPage/ ) and GreenGeeks are the best Dedicated ... for those who want to buy high quality ... , The IT manager of Top10BestSEOHosting.com says, “We ... recommended suppliers for everyone. A lot of the ...
(Date:10/19/2014)... been working in the garment industry for decades, LunaDress’ dress ... James, one of the company’s top designers, many ladies like ... that add beauty to them. Chiffon floor length outfits are ... new selection of 2014 long prom dresses. , As ... available in over 20 popular designs. The company intends to ...
(Date:10/19/2014)... Charlotte, NC (PRWEB) October 19, 2014 ... muscle building program has just been released to ... throughout the online body building and fitness community. ... the attention of DietsAndFitnessGuides.com's Vin Delmonico prompting an ... the experience of hitting what is commonly known ...
Breaking Medicine News(10 mins):Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 4Health News:Top10BestSEOHosting.com Considers iPage And GreenGeeks As The Best Dedicated Server Hosting Suppliers 2Health News:2014 Long Prom Dresses From LunaDress Now Available In Over 20 Popular Designs 2Health News:Visual Impact Frequency Training Review: Rusty Moore's Latest Fitness Guide Released 2
... ... series featuring personal stories of young adults with disabilities and adjusting to college life. ... Wellesley, MA ... how people obtain legal services, announced that its ChildRC.com web site now features a ...
... , WASHINGTON , Jan. 26 ... Dateline NBC documentary on patients who have insurance but not adequate ... to deal with the lack of legal accountability for insurers and ... , The nonprofit consumer group called upon Obama to close ...
... , , WASHINGTON , ... (ALEC) -- the nation,s largest nonpartisan individual membership association of state ... and Curt Schroder for filing House Bills 2053 ... own health care choices. Representatives Baker and Schroder will hold a ...
... field that often deals with changes over many generations ... lifetime? A lot, some scientists say. If recent recommendations are ... medical entrance and licensing exams, says an international group of ... January 26 issue of Proceedings of the National Academy ...
... consultation on the EU Clinical Trials Directive, ECCO ... its member organisations for adapting the Directive,s requirements to ... Since the implementation of the Directive in 2004, ... the detrimental effect it has had, particularly on international ...
... A Universit de Montral research team is developing a pill ... stop eating. "Mice deprived of leptin will not stop eating. ... Mose Bendayan, a pathology professor at the Universit de Montral ... Leptin regulates appetite in mammals and its levels decrease ...
Cached Medicine News:Health News:ChildRC.com Features “Acclimating To College Life In A Wheelchair” 2Health News:Obama: Make Equal Justice for Patients a State of the Union Pledge & Re-establish White House Office of Consumer Affairs 2Health News:Obama: Make Equal Justice for Patients a State of the Union Pledge & Re-establish White House Office of Consumer Affairs 3Health News:Pennsylvania Legislators Stand for Health Care Freedom 2Health News:Pennsylvania Legislators Stand for Health Care Freedom 3Health News:Pennsylvania Legislators Stand for Health Care Freedom 4Health News:Medical students may soon be tested on evolution 2Health News:Medical students may soon be tested on evolution 3Health News:European Cancer Organization supports a revision of the EU Clinical Trials Directive 2Health News:European Cancer Organization supports a revision of the EU Clinical Trials Directive 3Health News:A gimmick-free weight-loss pill in the works 2
Straight shafts with teeth and 5 mm tying platform. Wide serrated handle with polished finish. Teeth: 0.3 mm. Manufactured in titanium....
Ergotec Vetriretinal Instrument System. Extra fine angled tips (3 mm). 20 gauge shaft tapering to 23 gauge, 10 mm from tip. Overall length from rear rotation knob to tip....
Designed to securely hold scleral plugs during insertion and removal. The cross action handle is designed to reduce hand fatigue while grasping plug....
Ergotec Vetriretinal Instrument System. Ultra-fine 3.35 mm jaws. Angled 55 degrees. 20 gauge shaft. 30 mm in length. Blackened tip. Overall length from rear rotation knob to tip....
Medicine Products: